BB Alzheimer’s Disease Assessment
Tau–Amyloid Profiling for Cognitive Insight
This panel evaluates Alzheimer’s disease related brain changes using FDA-cleared blood-based biomarkers:
- Lumipulse® pTau217 / Aβ1-42 Plasma Ratio
- Phosphorylated Tau-217 (pTau217)
- Indicates neuronal injury and tau pathology
- β-Amyloid 1-42 (Aβ1-42)
- Reflects amyloid plaque accumulation in the brain
Why These Biomarkers Matter
Alzheimer’s disease develops silently—years before symptoms appear. These biomarkers provide early, clinically actionable insight into the underlying biology driving cognitive decline.
Together, these biomarkers provide a clear view across the Alzheimer’s continuum:
- Early detection before symptoms emerge
- Improved risk stratification
- More precise, personalized care planning
| Quick Facts | |
|---|---|
| Time to complete: 5–10 minutes | Sample type: At-home collection |
| Results: ~2–3 weeks | Privacy: Secure & confidential |
Frequently Asked Questions
Clarity you can act on. This testing is designed to give you clear, actionable insights—so you can make informed decisions with confidence. Below are answers to common questions to help guide you.
Want help interpreting your results? ExtendingMe Educators are available. Book a 30-minute one-on-one coaching session and receive personalized guidance tailored to your panel. (Applies to one panel per session.)